Antelope Surgical Solutions, Inc. is a New York-based clinical-stage biotech revolutionizing cancer care with innovative multimodal agents. Founded in 2020, the company’s flagship small molecule combines PET imaging, radiotherapeutics, and fluorescence-guided surgery, enabling precise, minimally invasive treatments. With patented syntheses and a robotic GMP manufacturing facility, Antelope is advancing its FDA-approved IND for prostate cancer and developing a versatile platform targeting multiple diseases. Antelope aims to become the “Tesla of Medicine and Surgery,” integrating diagnostics and therapeutics to redefine healthcare.
